Neuralink
$9Bpaper valuation
// OVERVIEW
Neuralink spent 8 years building a brain-computer interface that worked in pigs, then monkeys, then one human volunteer — while Synchron implanted its sixth patient and Precision Neuroscience completed its fifteenth clinical trial. Elon Musk's neurotechnology company is valued at $9 billion for technology that has demonstrated proof-of-concept in fewer humans than a Phase I drug trial.
// HQ
Fremont, United States
// STATUS
PRIVATE
// FOUNDED
2016
// TIER
The Unicorn Herd · $1B – $9.9B
// PRIMARY SECTOR
medtech
// FOUNDERS
// FUNDING ROUNDS
// SECTORS SERVED
// TECHNOLOGY
The N1 implant uses 1,024 flexible electrode threads thinner than human hair, inserted by a surgical robot into the motor cortex to decode neural signals and translate them into digital commands. The technology is genuinely impressive — wireless charging, hermetic titanium enclosure, real-time spike detection — but the fundamental challenge is not the engineering of the device but the biology of long-term biocompatibility and the regulatory pathway to commercial approval.
// WOWLS ASSESSMENT
Neuralink received FDA approval for human trials in May 2023 and implanted its first patient in January 2024 — eight years after founding. Synchron implanted its first patient in July 2022 with a less invasive endovascular approach that does not require opening the skull, has now treated sixteen patients across US and Australian trials, and is advancing toward pivotal trial enrollment. Precision Neuroscience's ultrathin cortical arrays have been temporarily implanted in over sixty patients during tumor resection surgeries to gather safety and efficacy data. The $9 billion valuation assumes Neuralink's superior electrode density will overcome its surgical invasiveness disadvantage — but every month of clinical delay while competitors accumulate safety data makes that assumption more expensive to validate.
// WHY WOWLS HUNTS THIS
The valuation prices in regulatory approval and commercial scale that competitors with less invasive devices will reach first. Musk's brand equity cannot accelerate FDA timelines.
// VALUATION NOTE
Valuation from August 2024 secondary share sale. Total funding approximately $680M across multiple rounds.
VERDICT: VAPORWARE ASCENDANT — Eight years and $680 million to implant one patient while Synchron enrolled sixteen with a catheter-based approach that does not require opening the skull
// PACK DEBATE
// PACK DEBATE — be the first to weigh in
Google account required — no spam, no nonsense
// LOADING INTEL…
// BROADCAST INTEL
// SIMILAR TARGETS
// INTEL UPDATED: MAY 2026
// INTELLIGENCE DISCLAIMER: Assessments represent editorial opinion based on publicly available data including filings, press reports, and market data as of the date shown. Valuations are approximate. Not financial or investment advice.
// FULL NETWORK ACCESS
🚀 Founder Briefing: Instantly sort investors by Sector, Stage, & Round — direct links to websites for all 1,030 unicorns & backing VCs included.
Don't just track Neuralink.
Master the entire 1,030 unicorn company intelligence network.
Stop analyzing tech monopolies one page at a time. Instantly filter, sort, and isolate the exact venture capital firms, angel investors, and corporate funds backing your specific market vertical. Find investors that fit your sector and deploy your pitch with direct outbound links to every target asset in the database — 1,030 targets total.
Acquire Intel →// 5 TIERS · PAYPAL SECURED
// ENGAGE THE FULL ARSENAL
Done reading on Neuralink?
Unlock the entire 1,030-company hitlist and 1,030 investor contacts.
Full structural breakdowns. Founder dossiers. VC outreach data. Threat-level intel updated continuously.
→ Deploy 5-Tier Order Form// ARBAN · ZUUN · MINGHAN · TUMEN · KHAN